Trials / Completed
CompletedNCT04556318
Identification of Differences in Breath Components Detected With IMS in Patients Tested on SARS-CoV-2 (COVID-19)
Study to Identify Differences of Exhaled Breath Components Using Ion Mobility Spectrometry (IMS) in Patients Tested Positive or Negative on SARS-CoV-2
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 396 (actual)
- Sponsor
- B. Braun Melsungen AG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Breath analysis is the evaluation of exhaled air of humans. It aims to get information about the clinical status of a human being by monitoring its volatile organic compounds (VOCs) in exhaled air. In this feasibility study it is intended to find specific biomarker(s) in exhaled breath indicating an infection with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Ion Mobility Spectrometry (IMS) | Two breathing gas samples will be taken from each study participant using ion mobility spectrometry with an ultrasound-based spirometer. The total sampling time is 1 minute (at least 5-7 breath takes) following an analysis time of 5-12 minutes. |
Timeline
- Start date
- 2020-09-23
- Primary completion
- 2021-06-11
- Completion
- 2021-06-11
- First posted
- 2020-09-21
- Last updated
- 2021-07-08
Locations
2 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT04556318. Inclusion in this directory is not an endorsement.